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Abstract 
Objective: Integrating mobile phone-based health (m-health) interventions into healthcare systems is one solution 
to improve access to services for the growing number of patients with chronic illness. Practical challenges such as 
poor recruitment and inadequate resource allocation can hamper the assessment of such interventions with clinical 
trial methodology. This paper highlights the challenges encountered during a pilot randomized controlled trial of 
an m-health medication adherence intervention and offers recommendations for future multi-site, non-drug clinical 
trials.
Results: Eighteen patients were recruited to the study; eight were randomly allocated to the intervention arm. 
Intervention participants responded to their daily medication-reminder text messages, indicating that medication 
had been taken or not, and nurses were able to organize their calls around their workload. The trial closed prema-
turely primarily due to inadequate numbers of eligible patients; however, other potentially resolvable feasibility issues 
were identified. These included lack of infrastructure at study sites, poor screening data acquisition and management 
processes, and inexperience in conducting supportive care trials at participating sites. M-health intervention trials are 
designed to inform implementation of best supportive care practice. Adequate skills and infrastructure are research 
prerequisites that require careful consideration and sufficient investment for the successful execution of multi-site 
supportive care trials.
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Introduction
Given the increasing number of people diagnosed with 
chronic disease [1, 2], the mounting pressure on health 
services and the fiscal restraints on health care [3], cost 
effective telehealth interventions integrated with tar-
geted, direct clinical contact are urgently required [4]. 
Mobile phone-based health (m-health) interventions 
have shown promise in improving oral drug adherence 
[5], however most trials have been methodologically 
flawed and none have yet been conducted in populations 
with cancer [6]. Oral tyrosine kinase inhibitor therapy 
is the standard of care for patients with chronic phase 
myeloid leukemia (CML); however, continuous, daily 
dosing is required for an indefinite period, often lifelong, 
to ensure treatment efficacy [7, 8]. Thus, optimal medica-
tion adherence is critical for patients with CML, making 
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this an important population in which to trial m-health 
interventions to improve medication adherence [5].
Therefore we developed the REMIND intervention 
package [9] to promote medication adherence and pro-
vide coaching in the self-management of side effects 
through mobile phone alerts, self-care advice, and nurse 
telephone consultations. REMIND consisted of two syn-
ergistically operating elements: nurse telephone consul-
tations to promote medication adherence and provide 
coaching in adverse effect self-management; and a 
m-health system comprising individually-tailored mobile 
phone alerts, to which patients were to text responses 
indicating that medication had been taken or not, with 
tailored self-management advice based on self-reported, 
weekly symptom assessment and medication adherence.
To evaluate REMIND we commenced a pilot rand-
omized-controlled trial. Eighteen patients were recruited 
before premature trial closure; the original target was 40 
patients. This brief research note explores the feasibility 
issues encountered during the pilot testing of REMIND, 
as well as possible solutions.
Main text
Methods
This study was conducted across three cancer centres 
in Australia and received authorisation to begin from 
the respective Human Research Ethics Committees. A 
detailed description of participant selection criteria, out-
come measures and data collection process are provided 
elsewhere [9]. Consenting patients were randomised (1:1) 
using a computer-generated randomisation chart.
The recruitment target was 40 participants over 
approximately four months. However, after 12  months, 
only 18 participants had been recruited which prompted 
study discontinuation due to process and resource issues. 




Despite the three participating sites initially confirming 
having sufficient CML patients to meet study timelines, 
most approached patients did not meet eligibility crite-
ria. The overestimation of the number of patients meet-
ing inclusion criteria, also known as Lasagna’s law [10, 
11] is a very common phenomenon in clinical trials. To 
ensure adequate recruitment rates for medication adher-
ence trials, patient inclusion criteria could be expanded 
to include other cancer types, other chronic disease types 
or clinical indications of unstable disease status. In addi-
tion, social networking could be employed to enable self-
referral to trials targeting low-incidence diseases [12].
Site‑related issues
Inadequate infrastructure at some participating sites, and 
a lack of understanding among staff about the focus of 
supportive care interventions affected study conduct and 
data collection. Specifically, the study protocol required 
Table 1 Problems experienced during the pilot study of REMIND
Problem Suggested solution
Recruitment Overestimation of the prevalence of patients diagnosed  
with CML within the past 2 years
Expand patient eligibility criteria to other conditions where 
medication adherence is critical for long-term survival; 
Add more recruitment sites
Infrastructure Limited computer availability on site to train participants as 
per protocol
Use versatile and portable devices such as tablet comput-
ers for research purposes. Where necessary, allocate 
appropriate devices to each site for the duration of the 
study period
Staff expertise Inadequate knowledge and understanding of supportive 
care research
Provide specific training in the purpose and conduct of sup-
portive care studies for clinical trial staff; collaborate with 
other hospital departments more familiar with supportive 
care methodologies (e.g. psychology and psychiatry)
Site visit Site initiation and monitoring conducted over the phone or 
by email
Adopt a combination of central and on-site visits; ideally, 
funding should support site initiation visits, then monitor-





Difficulty in coordinating routine blood testing with study 
commencement and baseline assessment
Pill count
Unused meditation packs and prescription refills not 
returned
Hospital was not the only place for meditation refills
Use of electronic pill monitoring device
Conduct secondary database analysis
Data collection Use of two separate online platforms for data collection Use of a single software application to capture and manage 
clinical data (e.g. REDCap)
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that patients be trained in the REMIND program by a 
study nurse at the beginning of the intervention. How-
ever, limited computer availability in the clinic area pre-
vented some patients from being trained as per protocol 
at one site, resulting in patient non-adherence to the 
intervention.
Another issue was the poor maintenance of clinic 
screening logs which are designed to record the recruit-
ment of a consecutive sample of patients to inform on 
the representativeness of participants within the clinical 
setting [13]. Poor documentation of the screening and 
recruitment process significantly affected the quality of 
the information collected with only information from eli-
gible participants’ being recorded. Without information 
about the total number of patients screened, ineligible, or 
declining participation, participants’ representativeness 
could not be established. Inadequate time and resource 
allocation may have prevented compliance with this pro-
cess. Additionally, staff inexperience with supportive 
care studies may also have contributed to the problem. 
While they had extensive expertise in the management of 
clinical drug trials, some were unfamiliar with the pur-
pose and priorities specific to supportive care trials, in 
particular aspects related to endpoints related to patient 
reported outcomes. From their experience with drug trial 
these outcomes were generally regarded as ‘an optional 
extra’. Specific training in the conduct of supportive care 
studies for clinical trial staff may be required and helpful 
to facilitate their conduct.
Site visits
Pre-study (or initiation) visits to recruiting centres are 
conducted to assess suitability of infrastructure and staff 
availability. Additionally, regular site monitoring vis-
its are important to ensure that trial conduct complies 
with protocols and good clinical practice (GCP) guide-
lines [14]. The site-related issues outlined above may 
have been identified and addressed prior to trial initia-
tion. However, budget restrictions only allowed for one 
site to receive an initiation visit, with no subsequent site 
monitoring visits. Therefore, the other two sites were 
initiated over the phone, and study monitoring was con-
ducted over the phone and by emails. This method is not 
as effective as in-person visits, for which more time is 
allocated providing an opportunity to re-emphasise the 
importance of study processes, discuss study specificities, 
and resolve problems.
However, pre-study and regular site monitoring visits 
are costly [15], and adequate funding should be sought 
to conduct these visits. When necessary, study protocol 
and procedural compliance can be monitored through a 
combination of central and on-site monitoring [16]. Just 
as appropriate expertise and investment is required to 
implement best supportive care practice [17], the same 
should be required for the conduct of these trials. It is 
critical that relevant GCP content is conveyed through 
staff training, particularly emphasising aspects of the 
study design or protocol which may be unfamiliar to 
staff members who are inexperienced with supportive 
care trials. This could entail training data managers from 
Clinical Trials units or collaborating with other hospi-
tal departments, such as psychology, who may be more 
familiar with supportive care research methods.
Tracking medication adherence
In conjunction with self-reported medication adherence, 
we attempted to objectively assess adherence via BCR-
ABL blood levels, a routinely performed test to monitor 
therapeutic drug response. However, the timing of BCR-
ABL blood testing seldom coincided with baseline test-
ing, which sometimes occurred 10 weeks prior to study 
commencement. Therefore, molecular testing was not 
a feasible endpoint. Other objective measures that were 
trialled in REMIND were pill counts and prescription 
refills. However, patients often forgot to return their used 
and unused medication, packs and prescription refill. 
Patients were also not consistently collecting their medi-
cation from the hospital, making tracking of prescription 
refills and pill counts an impossible task. Future studies 
should consider investing in medication adherence track-
ing devices such as electronic pill monitoring. Addition-
ally, analyses of population-based health databases such 
as health insurances for medication claims could also 
provide an objective measure of medication adherence 
[18].
Data collection
Online data collection greatly reduces the costs of mail-
ing out surveys, paying staff to remind patients to return 
completed surveys, and entering paper questionnaire 
data. However, even in this small study, four out of the 
18 patients encountered problems using the online ques-
tionnaire when the support of a data manager was not 
available. Furthermore, the intervention patients had 
two sets of usernames and passwords; one set for the 
online data collection platform and another for the self-
reported, weekly side-effects assessment, which caused 
confusion. The use of electronic surveys embedded on 
a single software application to capture and manage 
clinical data (e.g. REDCap [19]) would eliminate these 
problems for patients able to complete online surveys. 
Educating patients less familiar with online question-
naires through adequately trained staff members would 
keep costs to a minimum and reduce the risk of missing 
or incorrect data.
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Discussion
Clinical trials are crucial for the generation of evidence 
to effectively manage disease. Behavioural trials dif-
fer fundamentally from drug trials in the nature of their 
interventions, but the methodologies to establish effi-
cacy and effectiveness are the same [20]. Interventions 
in behavioural trials are usually more complex to define 
and standardise than those of drug trials. A main reason 
is the variation in participants’ characteristics and pref-
erences, which will influence their behaviour (e.g. medi-
cation adherence), and have an important impact on the 
estimated effect of the intervention [21]. Institutions and 
organisations conducting clinical trials usually have staff 
experienced in managing industry sponsored trials. Clin-
ical trial staff are regularly trained in the good conduct of 
these studies, and are frequently monitored for adequate 
data collection and reporting. Considerable time and 
money are invested to ensure robust infrastructure and 
rigorous trial conduct [22, 23]. The same rigour is diffi-
cult to maintain in publicly funded studies with leaner 
budgets [20, 24]. Failing to provide adequate training may 
lead to under-reporting, and possibly study discontinua-
tion [10, 25].
Despite the great potential that technology presents in 
delivering timely and cost-efficient supportive care pro-
grams for people requiring ongoing treatment, adequate 
resources to evaluate the efficacy of these intervention is 
imperative. If clinical trials units are to be allocated fund-
ing to conduct supportive care studies, careful evaluation 
of staff experience with, and infrastructure available to 
accommodate, supportive care studies is essential. It is 
important to continue to consider how to improve sup-
port for non-drug clinical trial research.
Limitations
A limitation of this study is the small sample of nurses 
and patients used to pilot test this intervention. As CML 
is a relatively rare disease, it was difficult and time con-
suming to recruit patients. Future trials should consider 
assessing the impact of telehealth packages upon oral 
medication adherence in different cancer types.
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